Group 1 - The core point of the article is that Wantong Development (600246.SH) has announced a draft for a restricted stock incentive plan for 2025, proposing to grant 94.5206 million shares, which accounts for 5% of the company's total share capital as of the announcement date [1] - The grant price for the restricted stock is set at 6.25 yuan per share [1] - The validity period of the incentive plan is from the date of the first grant of restricted stock until all granted restricted stocks are fully released from restrictions or repurchased and canceled, with a maximum duration of 60 months [1]

Core Viewpoint - Wantong Development (600246.SH) has announced a draft for a restricted stock incentive plan for 2025, proposing to grant 94.5206 million shares, which represents 5% of the company's total share capital as of the announcement date [1] Summary by Sections - **Incentive Plan Details** - The number of restricted shares to be granted is 94.5206 million [1] - The grant price is set at 6.25 yuan per share [1] - The effective period of the incentive plan lasts from the date of the first grant of restricted shares until all shares are either released from restrictions or repurchased, with a maximum duration of 60 months [1]

智通财经APP讯，凡拓数创(301313.SZ)披露2025年限制性股票激励计划(草案)，公司拟向激励对象(共计 85人)授予270万股限制性股票(其中首次授予220万股)，本激励计划限制性股票首次及预留授予价格为 14.97元/股。本激励计划有效期为自限制性股票首次授予之日起至激励对象获授的限制性股票全部归属 或作废失效之日止，最长不超过60个月。 ...

此次激励计划有效期自限制性股票登记完成之日起至激励对象获授的限制性股票全部解除限售或回购注 销之日止，最长不超过36个月。 智通财经APP讯，西大门(605155.SH)发布2025 年限制性股票激励计划(草案)，拟授予的限制性股票数量 为310.6万股，约占激励计划草案公告时公司股本总额的1.62%。本激励计划一次性授予，不设置预留权 益。授予价格为每股8.27元。 ...

浩瀚深度公告称，公司于2025年10月22日审议通过2025年限制性股票激励计划相关议案。按规定，公司 对激励计划内幕信息知情人在2025年4月23日至10月22日买卖公司股票情况进行查询。核查对象为内幕 信息知情人，他们均填报了登记表，公司向中国结算上海分公司查询并获书面证明。结果显示，自查期 间所有核查对象均无买卖公司股票行为，未发现信息泄露及内幕交易情形。 ...

Core Viewpoint - The article discusses the implementation of a restricted stock incentive plan by the company Mao Ge Ping, aimed at enhancing long-term incentive mechanisms and aligning the interests of shareholders, the company, and management [4]. Group 1: Financial Performance - In the first half of 2025, the company achieved a revenue of 2.59 billion yuan, representing a year-on-year growth of 31.3%, and a net profit attributable to shareholders of 670 million yuan, up 36.1% year-on-year [5]. - For the third quarter of 2025, sales on various platforms showed significant growth: Taobao increased by 25.4%, Douyin by 55.6%, and JD.com by 45.7% [5]. - During the "Double Eleven" sales event, sales continued to perform well, with Taobao, Douyin, and JD.com showing year-on-year growth of 60.5%, 39.8%, and 22.3% respectively [5]. Group 2: Market Position and Product Development - The company has strengthened its high-end beauty positioning, with significant growth in its main product categories and channels [6]. - The product range has expanded from makeup and skincare to include fragrances, with new series such as Guo Yun Ning Xiang and Wen Dao Dong Fang [6]. - The company has successfully entered high-end department stores, including Beijing SKP and Chongqing Xingguang 68, enhancing its offline presence [6]. Group 3: Sales Performance and Rankings - The company achieved notable rankings during the "Double Eleven" event, entering the top 20 in the beauty category on Tmall and ranking first in the domestic makeup category on JD.com [5]. - Several key products have performed exceptionally well, with annual sales exceeding 200,000 units for the Xiaojin Fan powder and over 100,000 units for the Caviar Cushion Foundation and Caviar Mask [5].

Core Viewpoint - The company has completed the repurchase and cancellation of a total of 2,045,200 restricted stocks due to the disqualification of certain incentive recipients, with a total repurchase amount of approximately 29.29 million yuan, which will reduce the total share capital from 2,386,293,256 shares to 2,384,248,056 shares [2][22][36]. Group 1 - The company repurchased and canceled 1,614,450 shares at a price of 15.64 yuan per share and 430,750 shares at a price of 9.38 yuan per share due to the disqualification of 198 incentive recipients [2][22]. - The total repurchase amount for the canceled shares was 29,290,433 yuan, accounting for 0.0857% of the total share capital before cancellation [22][36]. - The repurchase and cancellation procedures have been completed with the Shenzhen branch of China Securities Depository and Clearing Co., Ltd. [2][22]. Group 2 - The company’s stock incentive plan was approved through various board meetings and shareholder meetings, with independent directors expressing their agreement on the related proposals [3][4][5]. - The company has a structured approach to handling disqualified incentive recipients, including those who have left the company or failed to meet performance criteria [24][30]. - The repurchase prices for the restricted stocks were set at 15.64 yuan and 9.38 yuan, reflecting the initial grant prices without adjustments for dividends [26][27]. Group 3 - The company’s total share capital will be reduced to 2,384,248,056 shares following the cancellation of the restricted stocks [22][36]. - The repurchase of restricted stocks is part of the company's ongoing management of its equity incentive plan, ensuring that only eligible recipients retain their shares [24][30]. - The company has confirmed that the repurchase and cancellation will not materially affect its financial status or operational results [37].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、本次解除限售的限制性股票上市流通日为2025年11月18日。 2、因激励对象所在业务单元未达成100%解除限售条件的业绩考核目标，公司按照激励对象所在业务单 元业绩考核达成比例对相应限制性股票进行解除限售。本次申请解除限售的激励对象为279名，可解除 限售的限制性股票共计450,088股，占公司股本总额的0.0562%。除上述情况外，本次实施的限制性股票 激励计划与已披露的限制性股票激励计划不存在差异。 浙江苏泊尔股份有限公司（以下简称"公司"、"本公司"或"苏泊尔"）第八届董事会第十八次会议审议通 过了《关于2022年限制性股票激励计划第二个解除限售期解除限售条件成就的议案》，董事会认为《浙 江苏泊尔股份有限公司2022年限制性股票激励计划（草案）》（以下简称"2022年限制性股票激励计 划"）第二个解除限售期解除限售条件已成就，其中激励对象所在业务单元未达成100%解除限售条件的 业绩考核目标；根据2022年限制性股票激励计划相关规定及公司20 ...

Group 1 - The stock price of Enwei Pharmaceutical (301331) closed at 32.37 yuan on November 14, 2025, down 0.77%, with a turnover rate of 2.32% and a trading volume of 23,800 shares, amounting to a transaction value of 77.6852 million yuan [1] - On November 14, the net inflow of main funds was 1.1213 million yuan, indicating a positive short-term attitude from major investors towards the stock [3] - Enwei Pharmaceutical participated in the establishment of a venture capital fund with a contribution of 20 million yuan, accounting for 9.9502% of the total fund size of 201 million yuan, focusing on early and growth-stage companies in the medical and technology sectors [1][3] Group 2 - The company completed the second vesting period of its 2023 restricted stock incentive plan, with 760,200 shares vested, representing 0.7388% of the total share capital [1][3] - The vesting price for the shares was set at 13.48 yuan per share, and the company achieved a performance target with a 17.43% increase in revenue for 2024 compared to 2022, resulting in an 80% vesting ratio [1]

本公司董事会薪酬与考核委员会及全体委员保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海新相微电子股份有限公司（以下简称"公司"）于2025年11月3日召开第二届董事会第十三次会议， 审议通过了《关于公司〈2025年限制性股票激励计划（草案）〉及其摘要的议案》等相关议案。根据 《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券 法》"）《上市公司股权激励管理办法》（以下简称"《管理办法》"）等相关法律法规及《上海新相微 电子股份有限公司章程》（以下简称"《公司章程》"）的有关规定，公司对2025年限制性股票激励计划 （以下简称"本次激励计划"）拟激励对象的姓名和职务在公司内部进行了公示。董事会薪酬与考核委员 会结合公示情况对拟激励对象名单进行了核查，相关公示情况及核查情况如下： 一、公示情况及核查方式 （一）公司对拟激励对象的公示情况 公司于2025年11月4日在上海证券交易所网站（www.sse.com.cn）披露了《新相微2025年限制性股票激 励计划（草案）》（以下简称"《激励计划》"）《新相微 ...